Home Cart Sign in  
Chemical Structure| 159997-94-1 Chemical Structure| 159997-94-1

Structure of Biricodar
CAS No.: 159997-94-1

Chemical Structure| 159997-94-1

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Biricodar, a non-macrocyclic pipecolinate derivative, is multidrug resistance inhibitor.

Synonyms: VX-710

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Biricodar

CAS No. :159997-94-1
Formula : C34H41N3O7
M.W : 603.71
SMILES Code : O=C([C@H]1N(C(C(C2=CC(OC)=C(OC)C(OC)=C2)=O)=O)CCCC1)OC(CCCC3=CC=CN=C3)CCCC4=CC=CN=C4
Synonyms :
VX-710
MDL No. :MFCD28138411

Safety of Biricodar

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
Streptococcus pneumoniae ATCC 10015 100 μg/ml Evaluation of VX-710's effect on the MIC of ethidium bromide (EtBr), showing a significant reduction in EtBr MIC (16-fold). Antimicrob Agents Chemother. 2004 Nov;48(11):4171-6
Enterococcus faecalis ATCC 29212 100 μg/ml Evaluation of VX-710's effect on the MIC of ethidium bromide (EtBr), showing a significant reduction in EtBr MIC (8-fold). Antimicrob Agents Chemother. 2004 Nov;48(11):4171-6
Staphylococcus aureus ATCC 29213 100 μg/ml Evaluation of VX-710's effect on the MIC of ethidium bromide (EtBr), showing a significant reduction in EtBr MIC (31-fold). Antimicrob Agents Chemother. 2004 Nov;48(11):4171-6
NCI/ADR-RES cells 5 μM 72 h To evaluate the synergistic cytotoxic effect of Biricodar in combination with C6-ceramide on NCI/ADR-RES cells. Results showed that cell viability was 90% with Biricodar or C6-ceramide alone, but decreased to 22% when combined. Exp Cell Res. 2011 Jul 15;317(12):1736-45

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT00003847 Lung Cancer Phase 2 Terminated - United States, Arkansas ... More >> University of Arkansas for Medical Sciences Little Rock, Arkansas, United States, 72205 United States, Indiana Indiana University Cancer Center Indianapolis, Indiana, United States, 46202-5265 United States, Massachusetts Massachusetts General Hospital Cancer Center Boston, Massachusetts, United States, 02114 Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02115 Fallon Clinic Inc. Worcester, Massachusetts, United States, 01605 United States, Missouri St. John's Mercy Medical Center Saint Louis, Missouri, United States, 63141 United States, New York Roswell Park Cancer Institute Buffalo, New York, United States, 14263-0001 United States, North Carolina Duke Comprehensive Cancer Center Durham, North Carolina, United States, 27710 United States, Pennsylvania Fox Chase Cancer Center Philadelphia, Pennsylvania, United States, 19111 Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.66mL

0.33mL

0.17mL

8.28mL

1.66mL

0.83mL

16.56mL

3.31mL

1.66mL

 

Historical Records

Categories